Effect of Additional Clostridium butyricum on the Intestinal Flora of Chronic Hepatitis B Patients Treated with Entecavir

被引:5
作者
Lu, Yu-Xia [1 ]
Chang, Yi-Zhong [1 ]
Liang, Ping [2 ]
Yang, Chang-Qing [1 ]
机构
[1] Tongji Univ, Tongji Hosp, Inst Digest Dis, Dept Infect Dis,Dept Gastroenterol & Hepatol,Sch, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
[2] Tongji Univ, Tongji Hosp, Dept Lab Med, Sch Med, 389 Xin Cun Rd, Shanghai 200065, Peoples R China
基金
中国国家自然科学基金;
关键词
Chronic viral hepatitis B; Clostridium butyricum; Entecavir; Intestinal microflora; GUT-LIVER AXIS; MICROBIOTA; CIRRHOSIS; PATHOGENESIS; DISEASES;
D O I
10.1007/s40121-021-00463-1
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Introduction To explore the influence of intestinal flora on the occurrence, development and antiviral therapy of chronic hepatitis B (CHB), 16S rDNA amplification sequencing was performed to investigate the intestinal flora in CHB patients treated with entecavir (ETV) and Clostridium butyricum (CB). Methods CHB patients were divided into the ETV group (treatment with ETV alone) and ETV + CB group (treatment with ETV and CB). After 8-week treatment, feces samples were collected and processed for 16S rDNA amplicon sequencing; blood samples were collected for the biochemical, immunologic and virologic evaluations, which were compared between groups. Results ETV treatment for 8 weeks significantly decreased the serum levels of alanine aminotransferase (ALT), interleukin-6 (IL-6), IL-8, tumor necrosis factor-alpha (TNF-alpha) and HBV DNA compared to those before treatment, but there were no marked differences between the ETV group and ETV + CB group. The intestinal flora changed significantly in the CHB patients after ETV + CB treatment: there were marked differences in 13 unique species before treatment and 4 unique species after ETV + CB treatment; at the phylum level, the top five bacteria with significant difference between patients before treatment and ETV + CB patients were Firmicutes, Actinobacteria, Cyanobacteria, Euryarchaeota and Synergistetes. There were significant differences in 25 unique species in the ETV group and 4 unique species in the ETV + CB group; at the phylum level, the top five bacteria with significant difference between ETV patients and ETV + CB patients were Actinobacteria, Fusobacteria, Proteobacteria, Saccharibacteria and Synergistetes. Conclusion ETV treatment improves the serum biochemical, immunologic and virologic variables, but additional CB fails to further improve these variables. Of note, additional CB affects the intestinal flora in the CHB patients treated with ETV.
引用
收藏
页码:1519 / 1530
页数:12
相关论文
共 50 条
  • [31] Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs tenofovir
    Kim, Byung Gyu
    Park, Neung Hwa
    Lee, Seung Bum
    Lee, Hojune
    Lee, Byung Uk
    Park, Jae Ho
    Jung, Seok Won
    Jeong, In Du
    Bang, Sung-Jo
    Shin, Jung Woo
    JOURNAL OF VIRAL HEPATITIS, 2018, 25 (12) : 1565 - 1575
  • [32] Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
    Yu-Xia Lu
    Cheng-Zhi He
    Ying-Xin Wang
    Zi-Sheng Ai
    Ping Liang
    Chang-Qing Yang
    Infectious Diseases and Therapy, 2021, 10 : 241 - 252
  • [33] Comparison of incidence of hepatocellular carcinoma between chronic hepatitis B patients with cirrhosis treated with entecavir or tenofovir in Taiwan - a retrospective study
    Chen, Chien-Hung
    Chen, Chi-Yi
    Wang, Jing-Houng
    Lai, Hsueh-Chou
    Hung, Chao-Hung
    Lu, Sheng-Nan
    Peng, Cheng-Yuan
    AMERICAN JOURNAL OF CANCER RESEARCH, 2020, 10 (11): : 3882 - +
  • [34] Effect of Entecavir on the Intestinal Microflora in Patients with Chronic Hepatitis B: A Controlled Cross-Sectional and Longitudinal Real-World Study
    Lu, Yu-Xia
    He, Cheng-Zhi
    Wang, Ying-Xin
    Ai, Zi-Sheng
    Liang, Ping
    Yang, Chang-Qing
    INFECTIOUS DISEASES AND THERAPY, 2021, 10 (01) : 241 - 252
  • [35] Entecavir to Telbivudine Switch Therapy in Entecavir-Treated Patients with Undetectable Hepatitis B Viral DNA
    Kim, Dong Hyun
    Choi, Jong Won
    Seo, Jeong Hun
    Cho, Yong Suk
    Won, Sun Young
    Park, Byung Kyu
    Jeon, Han Ho
    Shin, Sang Yun
    Lee, Chun Kyon
    YONSEI MEDICAL JOURNAL, 2017, 58 (03) : 552 - 556
  • [36] Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B
    Wong, Vincent Wai-Sun
    Wong, Grace Lai-Hung
    Yiu, Karen Kar-Lum
    Chim, Angel Mei-Ling
    Chu, Shirley Ho-Ting
    Chan, Hoi-Yun
    Sung, Joseph Jao-Yiu
    Chan, Henry Lik-Yuen
    JOURNAL OF HEPATOLOGY, 2011, 54 (02) : 236 - 242
  • [37] Entecavir for the long-term treatment of chronic hepatitis B
    Gonzalez, Stevan A.
    Keeffe, Emmet B.
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2009, 7 (09) : 1053 - 1062
  • [38] Entecavir - options and obstacles of an effective treatment for chronic hepatitis B
    Cornberg, M.
    Manns, M. P.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2010, 135 (1-2) : 32 - 37
  • [39] Pharmacoeconomics of entecavir treatment for chronic hepatitis B
    You, Joyce H. S.
    Chan, Fredric W. H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2008, 9 (15) : 2673 - 2681
  • [40] Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine
    Lim, Young-Suk
    Han, Seungbong
    Heo, Nae-Yun
    Shim, Ju Hyun
    Lee, Han Chu
    Suh, Dong Jin
    GASTROENTEROLOGY, 2014, 147 (01) : 152 - 161